Monday, November 16, 2026AboutTipsSubscribe free
Media Mogul News
INDEPENDENT. UNBOUGHT. UNAFRAID.
LATEST
Health Freedom

TrumpRx Goes Live With Deep Discounts, and Real Questions the White House Should Answer

The new federal drug pricing site launched with 43 medicines and cuts up to 85 percent, but secret deal terms and cheaper generics complicate the victory lap.

TrumpRx Goes Live With Deep Discounts, and Real Questions the White House Should Answer

TrumpRx.gov is live. The White House launched its direct to consumer drug pricing site on February 5 after missing an initial January target, and the topline numbers are the kind that make Big Pharma executives reach for the antacids.

The site debuted with 43 drugs from five manufacturers, with more coming. Ozempic and injectable Wegovy, which listed between 1,028 and 1,349 dollars a month, drop as low as 199 dollars. Zepbound falls from 1,088 dollars to 299 dollars. Insulin products like NovoLog and Tresiba come in at 35 dollars a month. Across Pfizer's offerings, discounts run up to 85 percent.

Here is how it works. TrumpRx is not a pharmacy. It is a government search portal that routes you to the manufacturer's own platform to buy directly, in cash, with no insurance and no pharmacy benefit managers in the middle. The prices flow from most favored nation agreements that tie American costs to the lowest prices paid in comparable developed countries. Pfizer signed first in September 2025, and by spring 17 manufacturers covering roughly 86 percent of the branded drug market had joined.

Get the stories they're afraid to run — free. Join the newsletter →

President Trump framed the principle plainly, declaring that the United States is done subsidizing the health care of the rest of the world. On that point he is simply correct. Americans have been the piggy bank for global pharmaceutical profits for decades, paying multiples of what the same pill costs in Paris or Toronto. Even AARP commended the administration for standing up to the big drug companies.

But this publication does not do victory laps on Big Pharma's say so, and readers deserve the caveats. The terms of the Pfizer deal remain confidential, which means no independent analyst can verify what taxpayers gave up in return, including the tariff exemptions participating firms received through January 2029. Analysis of the launch lineup found that some listed drugs still cost more in America than abroad, in certain cases twice the international price. And more than half the featured medicines already have cheaper generic alternatives available elsewhere.

There is also the fine print for ordinary families: cash purchases through the site generally do not count toward insurance deductibles or out of pocket maximums, and insured patients with low copays may see little benefit. PhRMA, for its part, is howling about imported foreign price controls, which tells you the industry feels the squeeze.

The verdict so far: a real crack in the pricing racket, wrapped in secrecy that should make every taxpayer demand the receipts. Publish the deals. If the numbers are as good as advertised, sunlight will only help.

Sources

Questions readers ask

What is Media Mogul News?

Media Mogul News is an independent, reader-supported news site led by Chief Editor Nate Jurewicz. We cover the stories corporate media skips: political corruption, Big Pharma, the deep state, election integrity, cannabis freedom, crypto and the money behind all of it.

What is your political stance?

We are pro-liberty, pro-cannabis, anti-war and anti-corruption, and we hold both parties to the same standard. We are not a party outlet. When the people we agree with get something wrong, we say so.

How is Media Mogul funded?

By readers. We take no pharmaceutical advertising and no money from the industries we cover. Support comes from newsletter readers, donations and Media Mogul merchandise.